These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
30. Does urodynamic verification of overactive bladder determine treatment success? Results from a randomized placebo-controlled study. Malone-Lee JG; Al-Buheissi S BJU Int; 2009 Apr; 103(7):931-7. PubMed ID: 19281469 [TBL] [Abstract][Full Text] [Related]
31. Effects of tolterodine ER on patient-reported outcomes in sexually active women with overactive bladder and urgency urinary incontinence. Rogers RG; Bachmann G; Scarpero H; Jumadilova Z; Sun F; Morrow JD; Guan Z; Bavendam T Curr Med Res Opin; 2009 Sep; 25(9):2159-65. PubMed ID: 19601704 [TBL] [Abstract][Full Text] [Related]
32. Treating patients with overactive bladder syndrome with antimuscarinics: heart rate considerations. Andersson KE; Olshansky B BJU Int; 2007 Nov; 100(5):1007-14. PubMed ID: 17922785 [TBL] [Abstract][Full Text] [Related]
33. Long-term safety, tolerability, and efficacy of the novel anti-muscarinic agent imidafenacin in Japanese patients with overactive bladder. Homma Y; Yamaguchi O Int J Urol; 2008 Oct; 15(11):986-91. PubMed ID: 18761536 [TBL] [Abstract][Full Text] [Related]
34. Editorial comment on: Tolterodine treatment improves storage symptoms suggestive of overactive bladder in men treated with alpha-blockers. Dmochowski R Eur Urol; 2009 Sep; 56(3):542. PubMed ID: 19070419 [No Abstract] [Full Text] [Related]
35. Editorial comment on: Tolterodine treatment improves storage symptoms suggestive of overactive bladder in men treated with alpha-blockers. Speakman MJ Eur Urol; 2009 Sep; 56(3):542-3. PubMed ID: 19070420 [No Abstract] [Full Text] [Related]
37. Local effects of antimuscarinics. Masuda H; Kim YT; Tyagi S; Chancellor MB; de Miguel F; Yoshimura N Urol Clin North Am; 2006 Nov; 33(4):511-8, ix-x. PubMed ID: 17011387 [TBL] [Abstract][Full Text] [Related]
38. Pharmacological characterization of a novel investigational antimuscarinic drug, fesoterodine, in vitro and in vivo. Ney P; Pandita RK; Newgreen DT; Breidenbach A; Stöhr T; Andersson KE BJU Int; 2008 Apr; 101(8):1036-42. PubMed ID: 18279452 [TBL] [Abstract][Full Text] [Related]
39. Overactive bladder: treatment options in primary care medicine. Sussman DO J Am Osteopath Assoc; 2007 Sep; 107(9):379-85. PubMed ID: 17908830 [TBL] [Abstract][Full Text] [Related]
40. [Substantiation of the duration of m-cholinolytics administration in conservative treatment of hyperactive urinary bladder]. Danilov VV; Vol'nykh IIu; Danilova TI; Vodop'ianova OA; Kudriakova NA Urologiia; 2006; (5):71-4. PubMed ID: 17444156 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]